Celltrion is hoping patients make the jump from Johnson & Johnson and Merck blockbuster Remicade to its biosimilar, Remsima--and now it has real-world data to support a switch, just in time for partner Pfizer to launch its Inflectra brand in the U.S.
After Pfizer swallowed Hospira, it handed back Celltrion's rights to two knockoff versions of top-selling Roche cancer meds Herceptin and Rituxan. Now, there’s a new owner of those potentially lucrative rights--and it’s Teva.
Johnson & Johnson lost its court battle to shield Remicade from encroaching biosimilar competition. A U.S. court struck down J&J's key patent on the drug, clearing the way for Pfizer to launch its copy of the $4.5 billion drug.